The iMSC platform will be used to develop cell and gene therapies to treat acute, life-threatening conditions. Leaders on the board have experience in therapeutics for a range of conditions including osteoarthritis, trauma and respiratory diseases.
The board comprises:
1 Massimo Dominici, MD, professor of medical oncology at University Hospital of Modena and Reggio Emilia in Italy
2. Frank Barry, PhD, professor of cellular therapy and regenerative medicine at National University of Ireland Galway
3. Robert Deans, PhD, chief scientific officer at genome engineering company Synthego
4. Richard Maziarz, MD, a researcher at Oregon Health & Science University in Portland
5. Patricia Rocco, MD, PhD, a professor at the Federal University of Rio de Janeiro in Brazil
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
